Symyx IntelliChem Delivers New and Enhanced Functionality in Intelligent ELN Platform
News Jul 18, 2005
Symyx Technologies have announced the release of the Symyx IntelliChem iELN version 5.0 suites, advancing the company's intelligent electronic lab notebook (iELN) software.
Symyx IntelliChem's electronic lab notebook software enables scientists in pharmaceutical, biotechnology, chemical and energy companies to replace paper lab notebooks while increasing productivity and data accessibility.
The version 5.0 release expands the capabilities of electronic lab notebooks by introducing new tools for parallel experimentation, advanced enterprise-level workflow, and enhanced security functionality and performance. In addition, Symyx IntelliChem has strengthened its Formulations suite, the iELN product specifically designed for pharmaceutical formulators.
"The Symyx IntelliChem iELN is unique in its ability to provide an enterprise-level single platform for global research while at the same time providing tailored user interfaces that help scientists perform daily tasks more effectively," said Paul Nowak, chief operating officer of Symyx Technologies.
"The IntelliChem iELN version 5.0 release extends these strengths across research and development: the new features and enhancements were driven by our relationships with leading companies, and we are confident that the marketplace will benefit from the results."
3-D Printed Sugar Scaffolds Offer Sweet Solution for Tissue EngineeringNews
University of Illinois engineers built a 3-D printer that offers a sweet solution to making detailed structures that commercial 3-D printers can’t: Rather than a layer-upon-layer solid shell, it produces a delicate network of thin ribbons of hardened isomalt, the type of sugar alcohol used to make throat lozenges.READ MORE
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018